Tracking outcomes of uterine cavity conditions after hysteroscopy
Cohort Study of Intrauterine Diseases
This project will follow adults with endometrial polyps, hyperplasia, or cancer who undergo hysteroscopy to see if detailed clinical and pathology data can predict disease course over one year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT07048327 on ClinicalTrials.gov |
What this trial studies
This is a prospective cohort platform enrolling patients undergoing hysteroscopy or diagnostic curettage for intrauterine lesions. Investigators will collect medical, menstrual, and obstetric histories, physical and gynecological exams, imaging, laboratory tests, and pathology results at baseline. After hysteroscopic surgery, participants will be followed for one year to document disease progression and outcomes. The platform aims to link clinical data with pathology to deepen understanding of pathogenesis, risk factors, and optimize treatment strategies.
Who should consider this trial
Good fit: Adults aged 18–80 who require hysteroscopy or diagnostic curettage for intrauterine pathology and are willing and able to provide informed consent and complete one-year follow-up.
Not a fit: People who cannot tolerate hysteroscopy, are actively enrolled in other drug trials, or cannot commit to the study follow-up are unlikely to receive benefit from this cohort.
Why it matters
Potential benefit: If successful, the platform could enable earlier detection, better risk stratification, and more tailored treatments for uterine cavity diseases.
How similar studies have performed: Other large observational cohorts of endometrial pathology have clarified risk factors and outcomes, so this effort applies established methods while adding prospective local data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 18-80 years; * Patients requiring hysteroscopy or diagnostic curettage for intrauterine pathologies (e.g., endometrial hyperplasia, endometrial polyps, submucosal uterine fibroids, adenomyosis, or endometrial malignancies); * Willing and able to comply with follow-up requirements; * Signed informed consent obtained. Exclusion Criteria: * Concurrent participation in other drug clinical trials; * Contraindications to or inability to tolerate hysteroscopy/curettage procedures; * Unwilling or unable to provide informed consent; * Unwilling or unable to adhere to study protocols.
Where this trial is running
Wuhan, Hubei
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Wen W Wang, Dr.
- Email: petrawang@163.com
- Phone: +86 15927167698
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.